APPLICATION OF THE STOPP/START CRITERIA IN THE SURVEY OF MEDICATION USE IN ELDERLY PATIENTS WITH RENAL FAILURE

Aleksandra CATIĆ-DORĐEVIĆ1, Nikola STEFANOVIĆ1, Ivana STOŠIĆ2, Ivana DAMNJANOVIĆ1, Ivana MILANOVIĆ2, Novica BOJANIĆ1, Radmila VELIČKOVIĆ-RADOVANOVIC1,3

1 Faculty of Medicine, University of Nis, Nis, Serbia
2 Institute for Treatment and Rehabilitation „Niska Banja”, Nis, Serbia
3 Clinic of Nephrology, Clinical Centre Nis, Nis, Serbia

Received 25 Oct 2019, Accepted 19 Nov 2019
https://doi.org/10.31688/ABMU.2019.54.4.10

Address for correspondence: Aleksandra CATIĆ-DORĐEVIĆ
Faculty of Medicine, University of Nis, Nis, Serbia
Address: Faculty of Medicine, Bulevar Zorana Đinđića 81, 18000, Niš, Serbia
E-mail: aleksandra1610@yahoo.com; Phone +381 66 377 654

ABSTRACT

Introduction. The risk of inappropriate prescribing and inadequate drug use in the elderly population is growing with ageing associated physiological changes and polypharmacy due to increased number of chronic diseases. In order to optimize the therapy, numerous criteria have been developed which can help pharmacists and physicians to implement rational pharmacotherapy.

The objectives of the study were to survey the practice of medication use in patients older than 65 years with different stages of renal failure and to identify potentially inappropriate prescribing, as well as to justify the role of pharmacists in pharmacotherapy optimization.

Material and methods. This retrospective study included 100 patients with average age of 72.30±5.00 years. Demographic, clinical and pharmacotherapy data were collected from hospital discharge summary after one day hospital examination at the Clinic of Nephrology of Clinical Center Niš, Serbia. Potentially inadequate drugs were identified by STOPP

RéSUMÉ

Application des critères Stopp / Start dans une étude sur l’emploi de la médication chez les patients âgés souffrant d’insuffisance rénale

Introduction. Les changements physiologiques, l’augmentation du nombre de maladies chroniques et la polypharmacie augmentent le risque de prescription inappropriée et d’utilisation inadéquate de médicaments chez les personnes âgées. Afin d’optimiser le traitement, de nombreux critères ont été développés.

Le but de la recherche. L’étude avait pour objectif de passer en revue les médicaments chez les patients âgés de plus de 65 ans avec insuffisance rénale dans différents stades et d’identifier une prescription potentiellement inappropriée. Les résultats étaient liés au rôle des pharmaciens dans l’optimisation de la pharmacothérapie.

Méthodes. Cette étude rétrospective a porté sur 100 patients âgés en moyenne de 72,30 ±5,00 ans. Les données démographiques, cliniques et pharmacothérapeutiques ont été collectées sur la base du document
The geriatric population is considered to be over 65 years old, accounting for about 13% of the world’s population1. The World Health Organization (WHO) distinguishes the following categories within the geriatric population1,2:

- elderly people (60-74 years);
- old people (75-90 years) and;
- very old people (over 90 years).

Chronic health conditions are more prevalent among older adults, as well as multiple medications use. Polypharmacy (use of five or more medications daily) may increase the risk of inappropriate medications use, the development of adverse drug reactions, the appearance of drug-drug and drug-disease interactions. The risk of adverse drug reactions is also higher with age-related changes in pharmacokinetics and pharmacodynamics. Older adults have decreased function of liver and kidneys, reduced cognition, vision, hearing and mobility. Almost, a third of the total medications are consumed by older adults2. The pharmacists can help physicians in rationalization of pharmacotherapy by selecting the medication and setting the optimal dosage regimen. The pharmacists should be included in the healthcare team in order to optimize health outcomes.

Polypharmacy and inappropriate prescribing (IP) are risk factors for the occurrence of adverse effects that may be the cause of unfavorable clinical outcomes3. Polypharmacy is present in a large number of patients. It increases the risk of developing adverse reactions such as weight loss, falls, functional and cognitive impairment, leads to hospitalization, but is not associated with a greater survival of patients4. Inappropriate prescribing is present when the risk...
associated with use of prescribed drugs outweighs the potential benefit. The term Potentially Inappropriate Prescribing (PIP) includes not only misprescribing, but also overprescribing and underprescribing.

Polypharmacy is closely linked to the risk of PIP and increases linearly with the number of drugs used. The increase in the number of medications carries a risk of drug use without clinical indications, can reduce dependence of patients, but also can increase treatment costs.

In order to identify potentially inadequate prescribing and reduce the risk of adverse drug reaction, different criteria have been developed to help pharmacists when they assess the medication. Potentially inadequate medicines in the treatment of elderly adults which can change the benefit-risk ratio and increase the risk of adverse drug reactions, due to aging-induced changes, are identified by STOPP criteria (Screening Tool of Older Persons’ Prescriptions). Also, criteria for drugs which could be useful in certain indications in older patients have been established (Screening Tool to Alert doctors to Right Treatment – START). The criteria were developed in Ireland using “Delphi” consensus technique by 18 experts in the field of geriatric pharmacotherapy from academic centers of the Great Britain and Ireland. STOPP/START criteria have some advantages over the frequently used Beers criteria because they are conceived according to physiological systems and related to drug classes that facilitate their application. Also, special attention has been paid to the use of narcotic analgesics, drugs that can adversely affect people prone to falls, and the occurrence of therapy duplication (two drugs from the same pharmacotherapy group).

THE OBJECTIVE OF THE STUDY

The main objective of the study was to assess medication of geriatric patients with different stages of renal failure using STOPP and START criteria, in order to identify potential inappropriate prescribing. The second objective was to justify the role of pharmacist in the prescription of the rational and optimal pharmacotherapy in elderly patients.

MATERIAL AND METHODS

A retrospective study, which included 104 patients, was carried out at Clinic of Nephrology of Clinical Center Nis, Serbia, from March to May 2018. Demographic, clinical and pharmacotherapy data were collected on the basis of hospital discharge summary after one day hospital examination. The patients were older than 65 years, with renal failure and comorbidities (median 6.0). Four patients were excluded from the study due to incomplete therapy data. Analyzed data included: patients’ medical history, clinical and diagnostic findings, conclusions on the patient’s medical condition, prescribed therapy at discharge and additional advice. The most important data for evaluation of medication given to patients were gender, age, body mass index (BMI), potassium level, number of drugs and number of comorbidities per patient. Identification of potentially inappropriate drugs was performed using the STOPP/START criteria.

STOPP criteria include 65 clinically relevant statements that help healthcare providers identify Potentially Inappropriate Medications (PIMs). Each criterion was accompanied by a concise explanation of why the practice of prescribing is potentially inappropriate. START criteria comprise 22 statements indicating Potential Prescribing Omissions (PPOs).

The obtained data were statistically processed by software SPSS 16 and given in tabular form.

RESULTS

The demographic data of the homogenous group of patients are shown in Table 1. The results are expressed as the mean values with standard deviation (X±SD) and interquartile difference. The average age of the patients was 72.30±5.00 years. The study group comprised 56% males and 44% females. The average number of medications was 6.20±2.79 per patient. The average glomerular filtration rate showed a reduced renal function in all subjects (63.64±26.37 ml/min/1.73m²) (Table 1).

The results of the identified PIPs in accordance with the applied STOPP/START criteria are shown in Table 2. In total, 63 STOPP and 60 START criteria were identified. Inappropriately prescribed drugs were identified in 44%, while the absence of potentially useful drugs was recorded in 36% of patients. Presented PIPs are identified taking into account the number of comorbidities in patient and the number of drugs in the therapy. A statistically significant difference in the number of PIPs among the patients.
The most commonly identified STOPP/START criteria are shown in Table 3. The use of benzodiazepines was identified as the main reason for use of STOPP criteria. Therapeutic duplication was recorded in high percentage of cases too. The reasons for use of STOPP criteria were also the use of aspirin in patients without a history of coronary, cerebral or peripheral vascular symptoms or diseases and long-term use of digoxin (125 mg/daily) in patients with decreased renal function.

The most frequently identified START criterion was the absence of statins in patients with a documented history of coronary, cerebral or peripheral vascular diseases who were independent in performing basic activities of daily living (31.70% of total number of used START criteria). The use of START criteria related to the endocrine system prescribed pharmacotherapy was also recorded: as use of statins in diabetes mellitus type 2 with presence of major cardiovascular risk factors and use of metformin in diabetes mellitus type 2 with or without the presence of metabolic syndrome.

The results which show the impact of individual factors on the occurrence of PIP in accordance with the STOPP/START criteria are presented in Tables 4 and 5.

The number of comorbidities is found by logistic regression as the most significant factor which influences on the occurrence of START criteria.

The influence of patient’s gender, age, number of comorbidities and drugs on the occurrence of START criteria is shown in Table 5.

The number of comorbidities is found by logistic regression as the most significant factor which influences on the occurrence of START criteria.

**DISCUSSION**

Rational and appropriate drug prescribing for geriatric population is of great importance. It contributes to reduction of drug adverse effects, enables optimal health outcomes and may reduce the costs of additional treatment. Potentially inadequate therapy in the elderly patients is easier to identify by applying the criteria. In previous retrospective researches was registered the presence of polypharmacy in the elderly patients treatment, as well as the connection between polypharmacy and the occurrence of PIP.

Also, the role of pharmacists in PIP recognition by using criteria was justified. We have also registered the presence of polypharmacy and its association with...
Table 3. The most commonly identified STOPP/START criteria.

<table>
<thead>
<tr>
<th>Criteria</th>
<th>% patients</th>
<th>% of participation in relation to total number of STOPP</th>
<th>Criteria</th>
<th>% patients</th>
<th>% of participation in relation to total number of START</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzodiazepines</td>
<td>14</td>
<td>22.2</td>
<td>Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, where the patient's functional status remains independent for activities of daily living and life expectancy is greater than 5 years</td>
<td>19</td>
<td>31.70</td>
</tr>
<tr>
<td>Any duplicate drug class prescription e.g. two concurrent opiates, NSAID's SSRIs, loop diuretics, ACE inhibitors</td>
<td>11</td>
<td>17</td>
<td>Statin therapy in Diabetes mellitus if co-existing major cardiovascular risk factors present</td>
<td>13</td>
<td>21.70</td>
</tr>
<tr>
<td>Aspirin with no history of coronary, cerebral or peripheral vascular symptoms or occlusive event</td>
<td>9</td>
<td>14.29</td>
<td>Metformin with type 2 diabetes with or without metabolic syndrome</td>
<td>10</td>
<td>16.70</td>
</tr>
<tr>
<td>Long-term (i.e.&lt;1 month), long-acting benzodiazepines and benzodiazepines with long-acting metabolites</td>
<td>7</td>
<td>11.1</td>
<td>Angiotensin Converting Enzyme (ACE) inhibitor with chronic heart failure</td>
<td>4</td>
<td>6.67</td>
</tr>
<tr>
<td>Digoxin at a long-term dose&gt;125mg/day with impaired renal function</td>
<td>4</td>
<td>6.35</td>
<td>ACE inhibitor following acute myocardial infarction</td>
<td>4</td>
<td>6.67</td>
</tr>
</tbody>
</table>

Table 4. The influence of gender, age, number of comorbidities and drugs on the occurrence of STOPP criteria.

<table>
<thead>
<tr>
<th>Model</th>
<th>B</th>
<th>p</th>
<th>OR</th>
<th>95% CI. for OR Lower limit</th>
<th>Upper limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>GENDER( FEMALE)</td>
<td>.040</td>
<td>.926</td>
<td>1.041</td>
<td>.448</td>
<td>2.417</td>
</tr>
<tr>
<td>AGE (&gt;75 years)</td>
<td>-.430</td>
<td>.347</td>
<td>.050</td>
<td>.265</td>
<td>1.594</td>
</tr>
<tr>
<td>NUMBER OF COMORBIDITIES</td>
<td>-.103</td>
<td>.283</td>
<td>.902</td>
<td>.748</td>
<td>1.088</td>
</tr>
<tr>
<td>NUMBER OF DRUGS</td>
<td>.202</td>
<td>.027</td>
<td>1.223</td>
<td>1.023</td>
<td>1.463</td>
</tr>
<tr>
<td>Constant</td>
<td>-1.006</td>
<td>.111</td>
<td>.366</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 5. The influence of gender, age, number of comorbidities and drugs on the occurrence of START criteria

<table>
<thead>
<tr>
<th>Model</th>
<th>B</th>
<th>p</th>
<th>OR</th>
<th>95% CI. for OR Lower limit</th>
<th>Upper limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>GENDER( FEMALE)</td>
<td>-.221</td>
<td>.647</td>
<td>.802</td>
<td>.312</td>
<td>2.060</td>
</tr>
<tr>
<td>AGE (&gt;75 years)</td>
<td>.462</td>
<td>.344</td>
<td>1.587</td>
<td>.610</td>
<td>4.131</td>
</tr>
<tr>
<td>NUMBER OF COMORBIDITIES</td>
<td>.221</td>
<td>.043</td>
<td>1.247</td>
<td>1.007</td>
<td>1.543</td>
</tr>
<tr>
<td>NUMBER OF DRUGS</td>
<td>.177</td>
<td>.067</td>
<td>1.194</td>
<td>.988</td>
<td>1.443</td>
</tr>
<tr>
<td>Constant</td>
<td>-3.460</td>
<td>.000</td>
<td>.031</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
the number of drugs for the occurrence of STOPP criteria, in our research.

Our research has shown that the most commonly identified STOPP criteria are related to the use of benzodiazepines and to the presence of therapeutic duplication. Statins and metformin have been identified using the START criteria as potentially useful drugs which are missing in therapy. STOPP/START criteria for other drugs have been identified with considerably less significance or have not been identified. These results are in accordance with research conducted in Ireland on a large number of patients. The total number of identified STOPP criteria per patient is slightly higher than in the Ryan et al. survey. Increased frequency and number of STOPP criteria observed in the group of our respondents can be partly explained by the lack of direct communication between prescribing physicians and pharmacists, as well as the lack of electronic patient documentation that would contain important data useful when prescribing new drugs.

The use of the STOPP criteria showed that in 22% of our patients is identified long-term use of benzodiazepines. The use of these drugs in elderly patients should be carried out in a shorter period of time and only when there are clear indications for their use. In about 17% of subjects, the presence of duplication therapy was demonstrated, which is much higher in comparison with the results of the Cahiri et al. (5%). It was most commonly a combination of two drugs for the treatment of asthma from the group of anticholinergics or beta 2 receptor agonists, while in minority of cases there were two nitrate vasodilators. In 14% of patients the STOPP criteria were applied when identified the use of aspirin without history of coronary, cerebral or peripheral vascular symptoms or diseases.

The number of STOPP criteria registered in our previous research conducted in primary care patients in the city of Niš is in accordance with the obtained results of this study (0.23±0.05 versus 0.26±0.15). The frequency of fulfilled START criteria is consistent with the results of Ryan et al. Previous research in our country showed a significantly higher representation of START criteria at the level of primary health care.

The most commonly identified failures in prescribing drugs, using the START criteria are related to the cardiovascular and endocrine system. The absence of statins from prescribed therapy was observed in 19% of patients which is 31.70% of the total number of identified START criteria. The American College of Cardiology/American Heart Association (ACC/AHA) guidelines from 2018 define chronic kidney disease as a risk factor for the prevention of atherosclerotic cardiovascular disease and recommend the use of statins in these patients if they are not dialyzed. However, the results of individual studies show a higher incidence of adverse statin effects in reduced renal function, and each patient must be individually approached when considering these START criteria. In a significantly smaller number of patients, the absence of angiotensin converting enzyme inhibitors and metformin in therapy was observed. In 13% of patients, which is 21.70% out of the total applied START criteria, has been registered in endocrine system disorders. The criterion for the application of statins in patients with diabetes melitus type 2 has been the presence of the main cardiovascular risk factors. A lack of metformin has been identified in patients with diabetes melitus type 2 with or without the presence of metabolic syndrome (10%). According to our results, the absence of aspirin prescribing has not been registered, opposite to the findings of other researchers.

Statistical analyses were used to assess the influence of different factors on the occurrence of STOPP/START criteria. Gender of patients, age categories (65-74 years and above 75 years), the number of drugs in therapy and the number of comorbidities were evaluated. The most significant impact on the occurrence of STOPP criteria has the number of drugs, while the number of comorbidities is singled out as the most important factor for the START criteria.

In the randomized controlled study of Gallagher et al. it was reported that the application of STOPP/START criteria with intervention proposed by a clinical pharmacist, as a member of a health care team, significantly improved the appropriateness of prescribing. The assessment was performed by the Medication Appropriateness Index (35.7% risk reduction) and the Assessment of Underutilization Index (21.0% risk reduction). This improvement was sustained during the six-month period. The prevalence of failure of therapy and mortality was lower in the intervention group, but the differences were not statistically significant. A survey involving the application of STOPP/START criteria in order to assess the impact on quality of life has not been recorded yet. Direct costs of PIP and benefits of pharmacists’ interventions have been documented. In our survey, the pharmacoeconomic study has not been conducted due to lack of economic data.

**Conclusions**

The health care of the elderly population is a challenge for healthcare providers as well as for patients, their caregivers and the entire health system. The presence of a relatively high percentage of
inadequately prescribed drugs in the treatment of the elderly adults with different stages of renal failure has been registered in our research using STOPP and START criteria.

Application of STOPP and START criteria by pharmacist, associated with clinical findings provided by physician may reduce inappropriate use of polypharmacy, as well as avoid adverse effects of drugs. This approach offers numerous benefits to geriatric patients and improves everyday clinical practice.

The presence of potentially inadequate prescribing and the lack of potentially useful drugs in the complex pharmacotherapy of the elderly patients are the reasons for including pharmacists in a team which creates optimal pharmacotherapy for the elderly.

A pharmacist, as medication expert in interprofessional team, may have beneficial influence on health-related outcomes and pharmacoeconomic issues.

Compliance with Ethics Requirements:
“The authors declare no conflict of interest regarding this article”

“The authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008(5), as well as the national law. Informed consent was obtained from all the patients included in the study”

“No funding for this study”

References